Arcellx has a total of 72 patents globally, out of which 20 have been granted. Of these 72 patents, more than 93% patents are active. United States of America is where Arcellx has filed the maximum number of patents, followed by Japan and Europe. Parallelly, United States of America seems to be the main focused R&D center and is also the origin country of Arcellx. Arcellx’s initial public offering (IPO) has been declared for the month of February 2022 and the anticipation is building for its impending listing.
Arcellx was founded in the year 2014 by David Hilbert. Company is doing business in clinical-stage biopharmaceutical As of February 2022, Arcellx has a market valuation of $570.24 million.
Do read about some of the most popular patents of Arcellx which have been covered by us in this article and also you can find Arcellx’s patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Arcellx’s patent portfolio.
How many patents does the founder and the CEO of Arcellx have?
The founder and CEO, Sashi Narahari has 32 patents.
How many patents does Arcellx have?
Arcellx has a total of 72 patents globally. These patents belong to 6 unique patent families. Out of 72 patents, 67 patents are active.
How many Arcellx patents are Alive/Dead?
Worldwide Patents
Patent Families
How Many Patents did Arcellx File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Arcellx Applications Filed | Arcellx Patents Granted |
| 2016 | 30 | – |
| 2017 | 4 | – |
| 2018 | 24 | – |
| 2019 | – | – |
| 2020 | 5 | 4 |
| 2021 | 9 | 16 |
How Many Patents did Arcellx File in Different Countries?
Countries in which Arcellx Filed Patents
| Country | Patents |
| United States Of America | 9 |
| Japan | 5 |
| Europe | 5 |
| Hong Kong (S.A.R.) | 5 |
| Australia | 4 |
| Singapore | 4 |
| Canada | 4 |
| Israel | 4 |
| Brazil | 3 |
| Philippines | 3 |
| India | 3 |
| Korea (South) | 3 |
| Denmark | 2 |
| Mexico | 2 |
| Spain | 1 |
| Slovenia | 1 |
| Lithuania | 1 |
| Serbia | 1 |
| Indonesia | 1 |
| New Zealand | 1 |
| South Africa | 1 |
| Croatia | 1 |
| Germany | 1 |
| Poland | 1 |
| Hungary | 1 |
| Portugal | 1 |
Where are Research Centers of Arcellx Patents Located?
10 Best Arcellx Patents
WO2016164308A1 is the most popular patent in the Arcellx portfolio. It has received 16 citations so far from companies like Subdomain and L.E.A.F. Holdings Group
Below is the list of 10 most cited patents of Arcellx:
| Publication Number | Citation Count |
| WO2016164308A1 | 16 |
| WO2016164305A1 | 12 |
| WO2019099440A1 | 5 |
| US10662248B2 | 2 |
| US10647775B2 | 2 |
| US20180209983A1 | 2 |
| US20210002381A1 | 1 |
| KR1020180012747A | 1 |
| US20210401891A1 | 0 |
| US20210403517A1 | 0 |
What Percentage of Arcellx US Patent Applications were Granted?
Arcellx (Excluding its subsidiaries) has filed 7 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 3 have been granted leading to a grant rate of 75.0%.
Below are the key stats of Arcellx patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Arcellx?
| Law Firm | Total Application | Success Rate |
| Nixon & Vanderhye Pc | 7 | 75.00% |
List of Arcellx Patents
| Arcellx Patents | Title |
| US20210401891A1 | D-domain containing polypeptides and uses thereof |
| US20210403517A1 | D-domain containing polypeptides and uses thereof |
| US20210230288A1 | De novo binding domain containing polypeptides and uses thereof |
| US11008397B2 | De novo binding domain containing polypeptides and uses thereof |
| US20210023133A1 | Multifunctional immune cell therapies |
| US20210002381A1 | De novo binding domain containing polypeptides and uses thereof |
| US10662248B2 | De novo binding domain containing polypeptides and uses thereof |
| US10647775B2 | De novo binding domain containing polypeptides and uses thereof |
| US20180209983A1 | De novo binding domain containing polypeptides and uses thereof |
| EP3710034A4 | Multifunctional immune cell therapies |
| EP3903804A1 | De novo binding domain containing polypeptides and uses thereof |
| EP3710067A4 | D-domain containing polypeptides and uses thereof |
| EP3280433B1 | De novo binding domain containing polypeptides and uses thereof |
| EP3280432B8 | De novo binding domain containing polypeptides and uses thereof |
| CA3082410A1 | Multifunctional immune cell therapies |
| CA3082406A1 | D-domain containing polypeptides and uses thereof |
| CA2981616A1 | De novo binding domain containing polypeptides and uses thereof |
| CA2981711A1 | De novo binding domain containing polypeptides and uses thereof |
| WO2019099433A3 | D-domain containing polypeptides and uses thereof |
| WO2019099440A1 | Multifunctional immune cell therapies |
| WO2016164308A1 | De novo binding domain containing polypeptides and uses thereof |
| WO2016164305A1 | De novo binding domain containing polypeptides and uses thereof |
| AU2021200810A1 | De novo binding domain containing polypeptides and uses thereof |
| AU2016246426B2 | De novo binding domain containing polypeptides and uses thereof |
| AU2018369639A1 | D-domain containing polypeptides and uses thereof |
| AU2018368431A1 | Multifunctional immune cell therapies |
| JP2021503006A5 | Multifunctional immune cell therapy |
| JP2021502826A5 | D domain-containing polypeptide and its use |
| HK1249422A | De novo binding domain containing polypeptides and uses thereof |
| HK1249422A1 | De novo binding domain containing polypeptides and uses thereof |
| MX387517B | Polipeptides containing Novo union domains and use of them. |
| DK3280433T3 | de novo-binding domain containing polypeptides and uses thereof |
| ZA201706875B | De novo binding domain containing polypeptides and uses thereof |
| ES2866202T3 | polypeptides containing Novo union domains and use of them |
| SI3280432T1 | De novo binding domain containing polypeptides and uses thereof |
| HUE054435T2 | De novo binding domain containing polypeptides and uses thereof |
| PL3280432T3 | De novo binding domain containing polypeptides and uses thereof |
| DE602016063756T2 | DE-Novo binding domain with polypeptides and uses thereof |
| JP2021106605A | Novel binding domain-containing polypeptide and use thereof |
| RS61907B1 | De novo binding domain containing polypeptides and uses thereof |
| IL282704D0 | De novo binding domain containing polypeptides and uses thereof |
| HRP20210498T1 | De novo binding domain containing polypeptides and uses thereof |
| LT3280432T | De novo binding domain containing polypeptides and uses thereof |
| JP6873101B2 | Novel binding domain-containing polypeptide and its use |
| JP6871232B2 | Novel binding domain-containing polypeptide and its use |
| DK3280432T3 | Polypeptides containing the Novo binding domains and applications thereof |
| HK40034396A | D-domain containing polypeptides and uses thereof |
| PT3280432T | De novo binding domain containing polypeptides and uses thereof |
| HK40033094A | Multifunctional immune cell therapies |
| NZ774195A | De novo binding domain containing polypeptides and uses thereof |
| IDP000075612B | domain binder de novo containing polypeptides and its use |
| MX2020004933A | polypeptides containing domains d and their uses |
| PH12020550240A1 | D-domain containing polypeptides and uses thereof |
| PH12020550242A1 | Multifunctional immune cell therapies |
| BR112020008939A2 | Multifunctional immune cell therapies |
| BR112020009136A2 | polypeptides containing domain d and uses of the same |
| IN202027024691A | Multifunctional immune cell therapies |
| IN202027024698A | D-domain containing polypeptides and uses thereof |
| SG10202007987QA | De novo binding domain containing polypeptides and uses thereof |
| SG11201708257UB | De novo binding domain containing polypeptides and uses thereof |
| KR1020200096769A | d-domain containing polypeptides and uses thereof |
| KR1020200087176A | Multifunctional immune cell therapy |
| IL274652A | D-domain containing polypeptides and uses thereof |
| IL274677A | Multifunctional immune cell therapies |
| SG11202003169XA | D-domain containing polypeptides and uses thereof |
| SG11202003168WA | Multifunctional immune cell therapies |
| HK1249421A | De novo binding domain containing polypeptides and uses thereof |
| BR112017021308A2 | Polipeptídeos containing domain of connection of form and use of the same |
| PH12017501834A1 | De novo binding domain containing polypeptides and uses thereof |
| KR1020180012747A | De novo binding domain containing polypeptides and uses thereof |
| IL254907A | De novo binding domain containing polypeptides and uses thereof |
| IN201717036277A | De novo binding domain containing polypeptides and uses thereof |